期刊文献+

1,5-二芳基吡唑类环加氧酶-2选择性抑制剂的定量构效关系 被引量:5

Quantitative structure-activity relationship of the 1,5-diarylpyrazole class of cyclooxygenase-2 selective inhibitors
下载PDF
导出
摘要 目的 :探讨 1,5 二芳基吡唑类环加氧酶 2选择性抑制剂分子结构与活性定量关系 ,建立反映该类化合物构效关系的数学模型 ,为进一步药物设计提供理论依据 .方法 :按类型衍化出的先导化合物 ,采用多元回归分析方法 ,将 2 2个 5 取代吡唑化合物的环加氧酶 1抑制活性 ,环加氧酶 2抑制活性和抑制选择性与化合物疏水性参数logP ,取代基电性参数幃,立体参数MR进行相关及定量构效分析 .结果 :得到 3个反映该类抑制剂活性及选择性的定量构效关系 (QSAR)方程 :PIC50 ,COX -1=8.789838(1.76 81) - 0 .4 0 75 92 5 (0 .1839)logP ;PIC50 ,COX 2 =6 .4 374 34(0 .2 32 2 ) +0 .884 4 0 70 (0 .3487)logP 1.6 93330 (0 .5 0 0 3)Σ幃 ;Ps =- 6 1.18379(2 6 .10 91) +13.2 6 386(5 .5 6 937)logP - 0 .6 875 0 92 (0 .2 96 4 7) (logP) 2 .结论 :环加氧酶抑制选择性与疏水性呈抛物线关系 ;5位苯环 3,4位引入推电子基团或疏水性取代基 ,有利于提高该类化合物环加氧酶 2抑制活性 .所得QSAR方程可较好地预测该类化合物选择性抑制环加氧酶 AIM: To establish the QSAR models of the 1,5 diarylpyrazole class of COX 2 inhibitors and give the theoretical basis to guide the design of the new inhibitors. METHODS: Multiple correlation between activity and the physiochemical parameters of 22 derivatives was analyzed through the multiple regression analysis. RESULTS: According to the multiple regression analysis, three QSAR equations were acquired as follows: P IC50,COX 1 = 8.789838 (1.7681) -0.4075925(0.1839) logP;P IC50,COX 2 = 6.437434 (0.2322) +0.8844070(0.3487)logP-1.693330(0.5003)Σó; Ps= -61.18379(26.1091)+13.26386(5.56937)logP- 0.6875092 (0.29647)(logP) 2. CONCLUSION: In the series of 1, 5 diarylpyrazole, QSAR models reveal that the relationship between COX 2 selectivity and hydrophobic constant shows a parabolic change and that introduction of electron repelling and hydrophobic groups onto the 5 position of pheyl ring can raise the COX 2 inhibition activity.
出处 《第四军医大学学报》 北大核心 2003年第16期1523-1525,共3页 Journal of the Fourth Military Medical University
关键词 前列腺素内过氧化物合酶 选择性抑制剂 吡唑类 定量构效关系 prostaglandin endoperoxide synthase selective inhibitors pyrazoles quantitative structure activity relationships (QSAR)
  • 相关文献

参考文献12

  • 1[1]Villegas I, Alarcon De La Lastra C, Martin MJ, Motilva V, La Casa Garcia C. Gastric damage induced by subchronic administration of preferential cyclooxygenase-1 and cyclooxygenase-2 inhibitors in rats [J]. Pharmacology, 2002;66(2):68-75.
  • 2[2]Cipolla G, Crema F, Sacco S, Moro E, De Ponti F, Frigo G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: Current perspectives [J]. Pharmacol Res, 2002;46(1):1-6.
  • 3[3]Xie W, Chipman JG, Robertson DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing [J]. Proc Natl Acad Sci USA, 1991;88(6):2692-2696.
  • 4[4]Luong C, Miler A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID blinding site in the structure of human cyclooxygenase-2 [J]. Nat Strut Biol, 1996;3:927-933.
  • 5[5]Selinsky BS, Gupta K, Sharkey CT, Loll PJ. Structural analysis of NSAID binding by prostaglandin H2 synthase: Time-dependent and time-independent inhibitors elicit identical enzyme conformations [J]. Biochemistry, 2001;40(17):5172-5180.
  • 6[6]Kothekar V, Sahi S, Srinivasan M, Mohan A, Mishra J. Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: A computer modelling study [J]. Indian J Biochem Biophys, 2001;38(1-2):56-63.
  • 7[7]Penning TD, Talley JJ, Bertenshaw SR. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors [J]. J Med Chem, 1997;40(9):1347-1365.
  • 8[8]Wang LS, Zhi ZL. Molecular connectivity index and molecular structure activity [M]. First edition. Bejing: Chinese Environment Science Press, 1992:107-108.
  • 9[9]Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 [J]. Nature, 1994;367:243-249.
  • 10[10]Rieke CJ, Mulichak AM, Garavito RM, Smith WL. The role of arginine120 of human prostaglandin endoperoxide H synthase in the interaction with fatty acid and inhibitors [J]. J Bio Chem, 1999;274(24):17109-17114.

同被引文献24

  • 1郝丽丽,梅其炳,贾敏,曹蔚,曹晓林.塞来昔布抑制人结肠癌细胞SW-1116增殖并诱导其凋亡[J].第四军医大学学报,2004,25(12):1113-1116. 被引量:2
  • 2Li-liHAO Qi-bingMEI Bang-leZHANG MinJIA Xiao-qiangLI FengZHANG.PC-407 inhibited proliferation and induced apoptosis in human colon cancer SW-1116 cells[J].Acta Pharmacologica Sinica,2004,25(11):1509-1514. 被引量:2
  • 3Zhi-hong LU,Xiao-yun XIONG,Bang-le ZHANG,Guo-cheng LIN,Yu-xiang SHI,Zhen-guo LIU,Jing-ru MENG,Yu-mei ZHOU,Qi-bing MEI2.Evaluation of 2 celecoxib derivatives:analgesic effect and selectivity to cyclooxygenase-2/1[J].Acta Pharmacologica Sinica,2005,26(12):1505-1511. 被引量:1
  • 4Steven JS, Punitha S, Diana LS. Cyclooxygenase inhibitors: Drugs for cancer prevention [J]. Curr Opin Pharmcol, 2003;3(4):352-361.
  • 5Li HL, Zhang HW, Cheng DD, et al. JTE-522, a selective COX-2 inhibitor, inhibits cell proliferation and induces apoptosis in RL95-2 cells [J]. Acta Pharmcol Sin, 2002;23(7):631-637.
  • 6Williams CS, Watson AJ, Sheng H, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models [J]. Cancer Res, 2000; 60(11):6045-6051.
  • 7Li M, Wu XY, Xu XC. Induction of apoptosis in colon cancer cells by Cyclooxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway [J]. Clin Cancer Res, 2001; 7(4): 1010-1016.
  • 8John A, Daniel D, Scott K. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells [J]. Cancer Chem Pharmacol, 2002; 50(8): 277-284.
  • 9Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development [J]. Anticancer Drugs, 2002;13(2):127-137.
  • 10Jolly K, Cheng KK, Langman MJ. NSAIDs and gastrointestinal cancer prevention [J]. Drugs, 2002;62(6):945-956.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部